Login to Your Account



LSK doubles down on early oncology pipeline with Huntsman deal

By Marie Powers
News Editor

Friday, August 7, 2015
LSK Biopharma inked an exclusive license agreement with the University of Utah's Huntsman Cancer Institute (HCI) to develop and commercialize HCI-1401, an orally bioavailable, small-molecule, irreversible inhibitor of Bruton's tyrosine kinase (BTK). The new asset doubles the cancer pipeline for the Salt Lake City-based biotech, which earlier this year completed a phase I/II trial of its lead compound, apatinib mesylate (YN968D1), in solid tumors.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription